190 related articles for article (PubMed ID: 17222681)
1. Atorvastatin preserves renal function in chronic complete unilateral ureteral obstruction.
Michli E; Gulmi FA; Chou SY; Mooppan UM; Kim H
J Urol; 2007 Feb; 177(2):781-5. PubMed ID: 17222681
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin protects renal function in the rat with acute unilateral ureteral obstruction.
Kamdar C; Chou SY; Mooppan UM; Kim H; Gulmi FA
Urology; 2010 Apr; 75(4):853-7. PubMed ID: 20371061
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin ameliorates tubulointerstitial fibrosis and protects renal function in chronic partial ureteral obstruction cases.
Fitzgerald JP; Chou SY; Franco I; Mooppan UM; Kim H; Saini R; Gulmi FA
J Urol; 2009 Oct; 182(4 Suppl):1860-8. PubMed ID: 19692013
[TBL] [Abstract][Full Text] [Related]
4. High urinary flow accelerates renal injury in young rats with partial unilateral ureteral obstruction.
Nguyen HT; Wu HY; Baskin LS; Kogan BA
J Urol; 2000 Jun; 163(6):1904-7. PubMed ID: 10799225
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin ameliorates tissue damage of obstructed ureter in rats.
Chuang YH; Chuang WL; Huang SP; Liu CK; Huang CH
Life Sci; 2011 Nov; 89(21-22):795-805. PubMed ID: 21971118
[TBL] [Abstract][Full Text] [Related]
6. HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis.
Kuwahara N; Sasaki S; Kobara M; Nakata T; Tatsumi T; Irie H; Narumiya H; Hatta T; Takeda K; Matsubara H; Hushiki S
Int J Cardiol; 2008 Jan; 123(2):84-90. PubMed ID: 17434618
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin prevents the downregulation of aquaporin-2 receptor after bilateral ureteral obstruction and protects renal function in a rat model.
Danilovic A; Lopes RI; Sanches TR; Shimizu MH; Oshiro FM; Andrade L; Dénes FT; Seguro AC
Urology; 2012 Aug; 80(2):485.e15-20. PubMed ID: 22503765
[TBL] [Abstract][Full Text] [Related]
8. Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats.
Tanaka N; Katayama Y; Katsumata T; Otori T; Nishiyama Y
Brain Res; 2007 Sep; 1169():125-32. PubMed ID: 17706949
[TBL] [Abstract][Full Text] [Related]
9. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.
Bianchi S; Bigazzi R; Caiazza A; Campese VM
Am J Kidney Dis; 2003 Mar; 41(3):565-70. PubMed ID: 12612979
[TBL] [Abstract][Full Text] [Related]
10. Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction.
Mizuguchi Y; Miyajima A; Kosaka T; Asano T; Asano T; Hayakawa M
J Urol; 2004 Dec; 172(6 Pt 1):2456-9. PubMed ID: 15538290
[TBL] [Abstract][Full Text] [Related]
11. Post-stroke atorvastatin treatment reduces neurological deficits and mortality rate in the stroke-prone spontaneously hypertensive rat.
Hayashi A; Suzuki M; Ogawa Y; Sonoda R; Sasamata M
J Pharm Pharmacol; 2004 Jul; 56(7):893-8. PubMed ID: 15233868
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin improves sodium handling and decreases blood pressure in salt-loaded rats with chronic renal insufficiency.
Juncos LI; Martín FL; Baigorria ST; Pasqualini ME; Fiore MC; Eynard AR; Juncos LA; García NH
Nutrition; 2012 Sep; 28(9):e23-8. PubMed ID: 22698702
[TBL] [Abstract][Full Text] [Related]
13. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
[TBL] [Abstract][Full Text] [Related]
14. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Charlton-Menys V; DeMicco DA; Fuller JH;
Am J Kidney Dis; 2009 Nov; 54(5):810-9. PubMed ID: 19540640
[TBL] [Abstract][Full Text] [Related]
15. Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin.
Kohno H; Sakai T; Saito S; Okano K; Kitahara K
Exp Eye Res; 2007 Mar; 84(3):569-76. PubMed ID: 17208229
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin treatment in the short term: does it induce renoprotection or vasculoprotection in renal transplantation?
Navarro-Muñoz M; Bonet J; Bayés B; Lauzurica R; Blanco S; Romero R
Transplant Proc; 2007 Sep; 39(7):2259-63. PubMed ID: 17889157
[TBL] [Abstract][Full Text] [Related]
17. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
[TBL] [Abstract][Full Text] [Related]
18. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.
Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
Clin J Am Soc Nephrol; 2007 Nov; 2(6):1131-9. PubMed ID: 17942759
[TBL] [Abstract][Full Text] [Related]
19. Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9.
Souza-Costa DC; Figueiredo-Lopes L; Alves-Filho JC; Semprini MC; Gerlach RF; Cunha FQ; Tanus-Santos JE
Crit Care Med; 2007 Jan; 35(1):239-45. PubMed ID: 17133179
[TBL] [Abstract][Full Text] [Related]
20. Renal function during and after a temporary complete unilateral ureter obstruction in rats.
Provoost AP; Molenaar JC
Invest Urol; 1981 Jan; 18(4):242-6. PubMed ID: 7451084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
